5.10
+0.18(+3.66%)
Currency In USD
| Previous Close | 4.92 |
| Open | 5.01 |
| Day High | 5.5 |
| Day Low | 4.9 |
| 52-Week High | 7.39 |
| 52-Week Low | 1.11 |
| Volume | 1.28M |
| Average Volume | 1.7M |
| Market Cap | 100.34M |
| PE | -3.57 |
| EPS | -1.43 |
| Moving Average 50 Days | 2.44 |
| Moving Average 200 Days | 2.24 |
| Change | 0.18 |
If you invested $1000 in Annovis Bio, Inc. (ANVS) since IPO date, it would be worth $531.8 as of November 30, 2025 at a share price of $5.1. Whereas If you bought $1000 worth of Annovis Bio, Inc. (ANVS) shares 3 years ago, it would be worth $379.46 as of November 30, 2025 at a share price of $5.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annovis Announces Two Presentations at the CTAD 2025 Conference
GlobeNewswire Inc.
Nov 24, 2025 1:00 PM GMT
MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
GlobeNewswire Inc.
Nov 18, 2025 1:00 PM GMT
MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in plasma biomarkers pTau217, total tau, and brain-derived